Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in their interests in the company's ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific share transaction rather than a financial performance report.
Material Changes
The only material change disclosed is the acquisition of 29 ordinary shares by Mrs. V A Whyte on January 6, 2011. This transaction occurred through the Company's Share Reward Plan under the Dividend Reinvestment element at a price of £12.50 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly details a compliance notification under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investors to Verify
- The transaction involved the acquisition of 29 ordinary shares by Mrs. V A Whyte.
- The purchase price was £12.50 per share.
- The transaction date was January 6, 2011, with notification on January 10, 2011.
- The mechanism was the Dividend Reinvestment element of the Company's Share Reward Plan.